FY2029 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Invivyd in a research note issued on Tuesday, February 4th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $0.41 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.57) per share.

Other analysts also recently issued research reports about the stock. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research report on Monday. Finally, Morgan Stanley decreased their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Price Performance

NASDAQ:IVVD opened at $1.98 on Wednesday. The firm has a market capitalization of $236.85 million, a PE ratio of -1.01 and a beta of 0.61. The business’s fifty day moving average price is $0.55 and its 200 day moving average price is $0.83. Invivyd has a 12 month low of $0.35 and a 12 month high of $5.10.

Institutional Investors Weigh In On Invivyd

Several hedge funds have recently modified their holdings of the company. Proficio Capital Partners LLC acquired a new position in Invivyd in the 3rd quarter valued at $27,000. Barclays PLC grew its position in shares of Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after purchasing an additional 75,780 shares during the period. Cubist Systematic Strategies LLC grew its position in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the period. Renaissance Technologies LLC acquired a new position in Invivyd in the second quarter valued at $421,000. Finally, Marshall Wace LLP lifted its position in Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after buying an additional 31,992 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Invivyd news, Director Terrance Mcguire sold 86,545 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the sale, the director now owns 3,170,231 shares of the company’s stock, valued at $1,521,710.88. This represents a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is owned by corporate insiders.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.